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Mutagenesis in Norovirus in Response to Favipiravir Treatment
To the Editor: Chronic norovirus infection in immunocompromised patients can lead to mal absorption and other complications 1 ; currently, no treatment has proved to be effective. Favipir avir is an antiviral medication that has been approved for the treatment of influenza in Japan 2 and has been used by some as treatment for Ebola virus infection, with mixed results. 3 Pre clinical data have shown that favipiravir can in duce mutagenesis and impair norovirus infectiv ity in mice. 4 We used favipiravir to treat chronic norovirus infection in a 48yearold man with common variable immunodeficiency.
The patient had a long history of common variable immunodeficiency enteropathy, a condi tion characterized by diarrhea, malabsorption, and duodenal villous atrophy with intraepithelial lymphocytosis; it had previously been treated with immunosuppressive agents, including infliximab. Administration of parenteral nutrition caused un acceptable side effects in this patient. Serial polymerasechainreaction-positive stool samples obtained in July 2014 led to a diagnosis of chron ic norovirus infection. Six months later, Mycobacterium avium-associated bronchiolitis also devel oped and was treated with antimicrobial therapy and with oral glucocorticoids for airflow obstruc tion. Treatment with highdose intravenous im mune globulin, nitazoxanide, and ribavirin was ineffective against the norovirus infection.
We administered 6000 mg of favipiravir on day 1 in three divided doses, followed by 1200 mg twice daily. We used doses that had been evalu ated in a trial of treatment for Ebola virus infec tion (higher doses than have been used for in fluenza), on the basis of the predicted 50% inhibitory concentration, the impaired enteral absorption in the patient, and the absence of serious adverse events attributed to the drug when given at these doses during the trial for Ebola.
3 Administration of favipiravir was approved by the Royal Free London NHS Trust Drug and Therapeutics Committee, and collection of rec ords and samples for research was approved by the NHS Research Ethics Committee. Written informed consent from the patient was obtained for both the administration of the drug and the use of the data for this research.
With treatment, the patient's diarrhea and the use of adjunctive loperamide decreased, his body weight increased, and the norovirus viral load decreased (Fig. 1A, 1B, and 1C ). An increase in serum levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phospha tase on liverfunction testing prompted a treat ment interruption on day 19, and the patient's gastrointestinal symptoms promptly relapsed. Re introduction of favipiravir was associated with rapid deterioration in liverfunction test results and treatment interruption on day 6; on both occasions, he was also receiving intravenous levo floxacin. A third treatment course was attempted without a loading dose and after stopping treat ment with levofloxacin. The symptomatic re sponse was slower but notable (Fig. 1A) , albeit without sustained weight gain, and the results of liverfunction tests remained stable. Again, the patient had a relapse after discontinuation of favipiravir treatment due to a lack of available medication. Unfortunately, his pulmonary dis ease progressed, and he eventually died from respiratory failure. Viral deep sequencing 5 and phylogenetic analy sis of norovirus isolates obtained from the pa tient revealed a monophyletic clade containing substantial diversity (Fig. 1D) . The divergence point from other GII.4 sequences suggested ac quisition of the infection before 2002. During the first course of favipiravir treatment, there was apparent selection for a distinct viral variant (Fig. 1E) ; this variant also increased in frequency during the third course of treatment. At the consensus level, it differed from the dominant variant observed before or after treatment by 118 nonsynonymous substitutions throughout the ge nome. We also found increasing A→G and T→C minority singlenucleotide variants during favipir avir treatment (Fig. 1F ), as has been described for murine norovirus. 4 In summary, despite the presence of complex coexisting conditions, the patient in this case had some symptomatic response to favipiravir treat ment, along with evidence for selective pressure on the infecting norovirus population. Further study of favipiravir for chronic norovirus infec tion should be considered. 
Figure 1 (facing page). Clinical Course and Laboratory and Molecular Results.
Panel A shows the dose of loperamide (blue line), numbers of stools per day that are of type 6 or 7 on the Bristol stool scale (orange line), and numbers of stools per day that are of type 7 on the Bristol scale (purple dots) over time (daily data for each measure), in relation to periods of favipiravir treatment (light blue shading). Numbered arrows indicate times at which stool samples were obtained for viral sequencing. Panels B and C show the patient's body weight (Panel B) and the inverse norovirus cycling threshold (CT) value (equivalent to viral load) (Panel C) from stool samples obtained over the same period. Panel D shows a reconstructed capsid nucleotide maximum-likelihood phylogenetic tree containing the 8 consensus sequences from our patient and 2198 reference sequences from all norovirus GII.4 strains. Samples 8 and 10 from the patient were not included in the phylogenetic trees because they contained a mixture of two variants at close to 50% frequency; therefore, a reliable sample consensus sequence could not be obtained. The sequences from our patient (in blue) form a single, well-supported monophyletic clade that contains very high diversity. Previously characterized GII.4 strains are colored to match the strain label and are collapsed where appropriate for clarity. We found a similar pattern in phylogenetic trees that were reconstructed on the basis of the nonstructural polyprotein and VP2. Bootstrap support values are shown at key nodes. The scale bar indicates the expected number of nucleotide substitutions per site. In Panel E, each line represents an individual nucleotide variant and indicates the frequency of that variant through time, colored according to the position of the site within the genome. In the graph on the left, all variants are plotted. In the graph on the right, only the dominant variants during favipiravir therapy are plotted; because these variants undergo similar changes in frequency through time, they are likely to be found on the same viral haplotype. For Panel F, we calculated the number of each mutation type present in each deepsequencing sample and plotted the total number of variants and the number of mutation types (A→G, T→C, G→A, and C→T) through time in relation to the three periods of favipiravir treatment. The number of variants is the number of single-nucleotide variants present; therefore, an individual genome site can have up to three variants. The points represent the days on which deep-sequencing samples were obtained.
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Copyright © 2018 Massachusetts Medical Society. All rights reserved. 24 In patients with drug allergy, desensitization can reduce or eliminate the allergic response to the drug and facilitate the continuation of a specific treatment. Owing to a paucity of information regarding desensitization to olaparib, we developed a desensitization proto col for the drug.
A 49yearold woman presented with a plati numsensitive relapse of a highgrade serous peri toneal cancer with extensive peritoneal and pleural carcinomatosis and effusions. Testing for a germline BRCA1 mutation was positive. No second somatic mutation was found. The patient had a complete remission after the most recent platinumbased chemotherapy and then began receiving maintenance therapy with olaparib cap sules at a dose of 400 mg twice daily. After the patient received the first dose, an allergic reaction developed that was characterized by angioedema and cutaneous wheals. This allergic reaction de veloped reproducibly within approximately 3 hours after each administration of olaparib and lasted for several hours. Three rechallenge attempts with preventive applications of clemastine (a first generation H 1 antihistamine) or bilastine (a second generation H 1 antihistamine), with or without the administration of omalizumab (a recombinant, 
